Agreement between rheumatologist and patient-reported adherence to methotrexate in a US rheumatoid arthritis registry

Jeffrey R. Curtis, Aseem Bharat, Lang Chen, Jeffrey D. Greenberg, Leslie Harrold, Joel M. Kremer, Tanya Sommers, Dimitrios Pappas

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. Rheumatologists have limited tools to assess medication adherence. The extent to which methotrexate (MTX) adherence is overestimated by rheumatologists is unknown. Methods. We deployed an Internet survey to patients with rheumatoid arthritis (RA) participating in a US registry. Patient self-report was the gold standard compared to MTX recorded in the registry. Results. Response rate to the survey was 44%. Of 228 patients whose rheumatologist reported current MTX at the time of the most recent registry visit, 45 (19.7%) had discontinued (n = 19, 8.3%) or missed ≥ 1 dose in the last month (n = 26, 11.4%). For the subgroup whose rheumatologist also confirmed at the next visit that they were still taking MTX (n = 149), only 2.6% reported not taking it, and 10.7% had missed at least 1 dose. Conclusion. MTX use was misclassified for 13%-20% of patients, mainly because of 1 or more missed doses rather than overt discontinuation. Clinicians should be aware of suboptimal adherence when assessing MTX response.

Original languageEnglish (US)
Pages (from-to)1027-1029
Number of pages3
JournalJournal of Rheumatology
Volume43
Issue number6
DOIs
StatePublished - Jun 2016

Keywords

  • Adherence
  • Methotrexate
  • Persistence
  • Rheumatoid Arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Agreement between rheumatologist and patient-reported adherence to methotrexate in a US rheumatoid arthritis registry'. Together they form a unique fingerprint.

Cite this